APO Research
Talk to an analyst

APO RESEARCH · REPORT

Hospital Injectable Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Hospital Injectable Drugs Market Outlook and Growth Opportunities 2026

21 December 2025214 pages

Choose your research edition.

Industry ResearchHospital Injectable Drugs Industry Research Report 2026144 pages · $2,950 USDIndustry Growth & TrendsGlobal Hospital Injectable Drugs Industry Growth and Trends Forecast to 2032121 pages · $3,450 USDMarket StructureGlobal Hospital Injectable Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hospital Injectable Drugs Market Outlook and Growth Opportunities 2026214 pages · $4,250 USDMarket Analysis & ForecastGlobal Hospital Injectable Drugs Market Analysis and Forecast 2026-2032210 pages · $4,950 USD

Market perspective

The global Hospital Injectable Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Hospital Injectable Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Hospital Injectable Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Hospital Injectable Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Hospital Injectable Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Hospital Injectable Drugs market include Hospira (Pfizer Inc.), Baxter, Fresenius Kabi, Sandoz (Novartis), Hikma Pharmaceuticals PLC, Dr. Reddy’s Laboratories Ltd, Grifols, Nichi-Iko Group (Sagent) and Teva Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Hospital Injectable Drugs market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Hospital Injectable Drugs and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Hospital Injectable Drugs revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Hospital Injectable Drugs market.

Hospital Injectable Drugs Segment by Company

Hospira (Pfizer Inc.)

Baxter

Fresenius Kabi

Sandoz (Novartis)

Hikma Pharmaceuticals PLC

Dr. Reddy’s Laboratories Ltd

Grifols

Nichi-Iko Group (Sagent)

Teva Pharmaceutical

Otsuka

B.Braun

JW Life Science

Auromedics

Sanofi

Gland Pharma

Endo International PLC

Sichuan Kelun Pharmaceutical

Cisen Pharmaceutical

Shijiazhuang No. 4 Pharmaceutical

Shandong Hualu Pharmaceutical

CR Double-Crane

Hospital Injectable Drugs Segment by Type

Generic Sterile Injectables

Sterile Intravenous (IV) Solutions

Hospital Injectable Drugs Segment by Application

Oncology

Anesthesia

Anti-Infectives

Parenteral Nutrition

Cardiovascular Diseases

Hospital Injectable Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Hospital Injectable Drugs status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Hospital Injectable Drugs key companies, revenue, market share, and recent developments.

3. To split the Hospital Injectable Drugs breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Hospital Injectable Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Hospital Injectable Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Hospital Injectable Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hospital Injectable Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hospital Injectable Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hospital Injectable Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Hospital Injectable Drugs industry.

Chapter 3: Detailed analysis of Hospital Injectable Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Hospital Injectable Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Hospital Injectable Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Hospital Injectable Drugs Industry Trends Table 2. Hospital Injectable Drugs Industry Drivers Table 3. Hospital Injectable Drugs Industry Opportunities and Challenges Table 4. Hospital Injectable Drugs Industry Restraints Table 5. Global Hospital Injectable Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Hospital Injectable Drugs Revenue Share by Company (2021-2026) Table 7. Global Hospital Injectable Drugs Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Hospital Injectable Drugs Key Company Manufacturing Base & Headquarters Table 9. Global Hospital Injectable Drugs Company, Product Type & Application Table 10. Global Hospital Injectable Drugs Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Hospital Injectable Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Generic Sterile Injectables Table 15. Significant Companies of Sterile Intravenous (IV) Solutions Table 16. Global Hospital Injectable Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Hospital Injectable Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Hospital Injectable Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Hospital Injectable Drugs Sales Value Share by Type (2021-2026) Table 20. Global Hospital Injectable Drugs Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Oncology Table 22. Significant Companies of Anesthesia Table 23. Significant Companies of Anti-Infectives Table 24. Significant Companies of Parenteral Nutrition Table 25. Significant Companies of Cardiovascular Diseases Table 26. Global Hospital Injectable Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Hospital Injectable Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Hospital Injectable Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Hospital Injectable Drugs Sales Value Share by Application (2021-2026) Table 30. Global Hospital Injectable Drugs Sales Value Share by Application (2027-2032) Table 31. Global Hospital Injectable Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Hospital Injectable Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Hospital Injectable Drugs Sales Value Share by Region (2021-2026) Table 34. Global Hospital Injectable Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Hospital Injectable Drugs Sales Value Share by Region (2027-2032) Table 36. Global Hospital Injectable Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Hospital Injectable Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Hospital Injectable Drugs Sales Value Market Share by Country (2021-2026) Table 39. Global Hospital Injectable Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Hospital Injectable Drugs Sales Value Market Share by Country (2027-2032) Table 41. Hospira (Pfizer Inc.) Company Information Table 42. Hospira (Pfizer Inc.) Business Overview Table 43. Hospira (Pfizer Inc.) Hospital Injectable Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Hospira (Pfizer Inc.) Hospital Injectable Drugs Product Portfolio Table 45. Hospira (Pfizer Inc.) Recent Development Table 46. Baxter Company Information Table 47. Baxter Business Overview Table 48. Baxter Hospital Injectable Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Baxter Hospital Injectable Drugs Product Portfolio Table 50. Baxter Recent Development Table 51. Fresenius Kabi Company Information Table 52. Fresenius Kabi Business Overview Table 53. Fresenius Kabi Hospital Injectable Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Fresenius Kabi Hospital Injectable Drugs Product Portfolio Table 55. Fresenius Kabi Recent Development Table 56. Sandoz (Novartis) Company Information Table 57. Sandoz (Novartis) Business Overview Table 58. Sandoz (Novartis) Hospital Injectable Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Sandoz (Novartis) Hospital Injectable Drugs Product Portfolio Table 60. Sandoz (Novartis) Recent Development Table 61. Hikma Pharmaceuticals PLC Company Information Table 62. Hikma Pharmaceuticals PLC Business Overview Table 63. Hikma Pharmaceuticals PLC Hospital Injectable Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Hikma Pharmaceuticals PLC Hospital Injectable Drugs Product Portfolio Table 65. Hikma Pharmaceuticals PLC Recent Development Table 66. Dr. Reddy’s Laboratories Ltd Company Information Table 67. Dr. Reddy’s Laboratories Ltd Business Overview Table 68. Dr. Reddy’s Laboratories Ltd Hospital Injectable Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Dr. Reddy’s Laboratories Ltd Hospital Injectable Drugs Product Portfolio Table 70. Dr. Reddy’s Laboratories Ltd Recent Development Table 71. Grifols Company Information Table 72. Grifols Business Overview Table 73. Grifols Hospital Injectable Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Grifols Hospital Injectable Drugs Product Portfolio Table 75. Grifols Recent Development Table 76. Nichi-Iko Group (Sagent) Company Information Table 77. Nichi-Iko Group (Sagent) Business Overview Table 78. Nichi-Iko Group (Sagent) Hospital Injectable Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Nichi-Iko Group (Sagent) Hospital Injectable Drugs Product Portfolio Table 80. Nichi-Iko Group (Sagent) Recent Development Table 81. Teva Pharmaceutical Company Information Table 82. Teva Pharmaceutical Business Overview Table 83. Teva Pharmaceutical Hospital Injectable Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Teva Pharmaceutical Hospital Injectable Drugs Product Portfolio Table 85. Teva Pharmaceutical Recent Development Table 86. Otsuka Company Information Table 87. Otsuka Business Overview Table 88. Otsuka Hospital Injectable Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Otsuka Hospital Injectable Drugs Product Portfolio Table 90. Otsuka Recent Development Table 91. B.Braun Company Information Table 92. B.Braun Business Overview Table 93. B.Braun Hospital Injectable Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. B.Braun Hospital Injectable Drugs Product Portfolio Table 95. B.Braun Recent Development Table 96. JW Life Science Company Information Table 97. JW Life Science Business Overview Table 98. JW Life Science Hospital Injectable Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. JW Life Science Hospital Injectable Drugs Product Portfolio Table 100. JW Life Science Recent Development Table 101. Auromedics Company Information Table 102. Auromedics Business Overview Table 103. Auromedics Hospital Injectable Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Auromedics Hospital Injectable Drugs Product Portfolio Table 105. Auromedics Recent Development Table 106. Sanofi Company Information Table 107. Sanofi Business Overview Table 108. Sanofi Hospital Injectable Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Sanofi Hospital Injectable Drugs Product Portfolio Table 110. Sanofi Recent Development Table 111. Gland Pharma Company Information Table 112. Gland Pharma Business Overview Table 113. Gland Pharma Hospital Injectable Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Gland Pharma Hospital Injectable Drugs Product Portfolio Table 115. Gland Pharma Recent Development Table 116. Endo International PLC Company Information Table 117. Endo International PLC Business Overview Table 118. Endo International PLC Hospital Injectable Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Endo International PLC Hospital Injectable Drugs Product Portfolio Table 120. Endo International PLC Recent Development Table 121. Sichuan Kelun Pharmaceutical Company Information Table 122. Sichuan Kelun Pharmaceutical Business Overview Table 123. Sichuan Kelun Pharmaceutical Hospital Injectable Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Sichuan Kelun Pharmaceutical Hospital Injectable Drugs Product Portfolio Table 125. Sichuan Kelun Pharmaceutical Recent Development Table 126. Cisen Pharmaceutical Company Information Table 127. Cisen Pharmaceutical Business Overview Table 128. Cisen Pharmaceutical Hospital Injectable Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. Cisen Pharmaceutical Hospital Injectable Drugs Product Portfolio Table 130. Cisen Pharmaceutical Recent Development Table 131. Shijiazhuang No. 4 Pharmaceutical Company Information Table 132. Shijiazhuang No. 4 Pharmaceutical Business Overview Table 133. Shijiazhuang No. 4 Pharmaceutical Hospital Injectable Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 134. Shijiazhuang No. 4 Pharmaceutical Hospital Injectable Drugs Product Portfolio Table 135. Shijiazhuang No. 4 Pharmaceutical Recent Development Table 136. Shandong Hualu Pharmaceutical Company Information Table 137. Shandong Hualu Pharmaceutical Business Overview Table 138. Shandong Hualu Pharmaceutical Hospital Injectable Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 139. Shandong Hualu Pharmaceutical Hospital Injectable Drugs Product Portfolio Table 140. Shandong Hualu Pharmaceutical Recent Development Table 141. CR Double-Crane Company Information Table 142. CR Double-Crane Business Overview Table 143. CR Double-Crane Hospital Injectable Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 144. CR Double-Crane Hospital Injectable Drugs Product Portfolio Table 145. CR Double-Crane Recent Development Table 146. Research Programs/Design for This Report Table 147. Authors List of This Report Table 148. Secondary Sources Table 149. Primary Sources List of Figures Figure 1. Hospital Injectable Drugs Product Image Figure 2. Global Hospital Injectable Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Hospital Injectable Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Hospital Injectable Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Generic Sterile Injectables Image Figure 8. Sterile Intravenous (IV) Solutions Image Figure 9. Global Hospital Injectable Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Hospital Injectable Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Hospital Injectable Drugs Sales Value Share by Type (2021-2032) Figure 12. Oncology Image Figure 13. Anesthesia Image Figure 14. Anti-Infectives Image Figure 15. Parenteral Nutrition Image Figure 16. Cardiovascular Diseases Image Figure 17. Global Hospital Injectable Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Hospital Injectable Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Hospital Injectable Drugs Sales Value Share by Application (2021-2032) Figure 20. Global Hospital Injectable Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Hospital Injectable Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Hospital Injectable Drugs Sales Value (2021-2032) & (US$ Million) Figure 23. North America Hospital Injectable Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Hospital Injectable Drugs Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Hospital Injectable Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Hospital Injectable Drugs Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Hospital Injectable Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Hospital Injectable Drugs Sales Value (2021-2032) & (US$ Million) Figure 29. South America Hospital Injectable Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Hospital Injectable Drugs Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Hospital Injectable Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Hospital Injectable Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Hospital Injectable Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Hospital Injectable Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Hospital Injectable Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Hospital Injectable Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Hospital Injectable Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Hospital Injectable Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Hospital Injectable Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Hospital Injectable Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Hospital Injectable Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Hospital Injectable Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Hospital Injectable Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Hospital Injectable Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Hospital Injectable Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Hospital Injectable Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Hospital Injectable Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Hospital Injectable Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Hospital Injectable Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Hospital Injectable Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Hospital Injectable Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Hospital Injectable Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Hospital Injectable Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Hospital Injectable Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Hospital Injectable Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Hospital Injectable Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Hospital Injectable Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Hospital Injectable Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Hospital Injectable Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Hospital Injectable Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Hospital Injectable Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Hospital Injectable Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Hospital Injectable Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Hospital Injectable Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Hospital Injectable Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Hospital Injectable Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Hospital Injectable Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Hospital Injectable Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Hospital Injectable Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Hospital Injectable Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Hospital Injectable Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Hospital Injectable Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Hospital Injectable Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Hospital Injectable Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Hospital Injectable Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Hospital Injectable Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Hospital Injectable Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Hospital Injectable Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Hospital Injectable Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Hospital Injectable Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Hospital Injectable Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Hospital Injectable Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Hospital Injectable Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Hospital Injectable Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Hospital Injectable Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Hospital Injectable Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Hospital Injectable Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Hospital Injectable Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Hospital Injectable Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Hospital Injectable Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Hospital Injectable Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Hospital Injectable Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Hospital Injectable Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Hospital Injectable Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Hospital Injectable Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Hospital Injectable Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Hospital Injectable Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Hospital Injectable Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Hospital Injectable Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Hospital Injectable Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Hospital Injectable Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Hospital Injectable Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Hospital Injectable Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Hospital Injectable Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Hospital Injectable Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Hospital Injectable Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Hospital Injectable Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Hospital Injectable Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Hospital Injectable Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Hospital Injectable Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Hospital Injectable Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Hospital Injectable Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Hospital Injectable Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Hospital Injectable Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Hospital Injectable Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Generic Sterile Injectables
  • Sterile Intravenous (IV) Solutions
Applications
  • Oncology
  • Anesthesia
  • Anti-Infectives
  • Parenteral Nutrition
  • Cardiovascular Diseases
Companies covered
  • Hospira (Pfizer Inc.)
  • Baxter
  • Fresenius Kabi
  • Sandoz (Novartis)
  • Hikma Pharmaceuticals PLC
  • Dr. Reddy’s Laboratories Ltd
  • Grifols
  • Nichi-Iko Group (Sagent)
  • Teva Pharmaceutical
  • Otsuka
  • B.Braun
  • JW Life Science
  • Auromedics
  • Sanofi
  • Gland Pharma
  • Endo International PLC
  • Sichuan Kelun Pharmaceutical
  • Cisen Pharmaceutical
  • Shijiazhuang No. 4 Pharmaceutical
  • Shandong Hualu Pharmaceutical
  • CR Double-Crane

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Hospital Injectable Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Hospital Injectable Drugs Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Hospital Injectable Drugs Market Dynamics
  1. 2.1 Hospital Injectable Drugs Industry Trends
  2. 2.2 Hospital Injectable Drugs Industry Drivers
  3. 2.3 Hospital Injectable Drugs Industry Opportunities and Challenges
  4. 2.4 Hospital Injectable Drugs Industry Restraints
3 Hospital Injectable Drugs Market by Company
  1. 3.1 Global Hospital Injectable Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Hospital Injectable Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Hospital Injectable Drugs Company Ranking (2024-2026)
  4. 3.4 Global Hospital Injectable Drugs Company Manufacturing Base and Headquarters
  5. 3.5 Global Hospital Injectable Drugs Company Product Type and Application
  6. 3.6 Global Hospital Injectable Drugs Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Hospital Injectable Drugs Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Hospital Injectable Drugs Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Hospital Injectable Drugs Market by Type
  1. 4.1 Hospital Injectable Drugs Type Introduction
  2. 4.1.1 Generic Sterile Injectables
  3. 4.1.2 Sterile Intravenous (IV) Solutions
  4. 4.2 Global Hospital Injectable Drugs Sales Value by Type
  5. 4.2.1 Global Hospital Injectable Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Hospital Injectable Drugs Sales Value by Type (2021-2032)
  7. 4.2.3 Global Hospital Injectable Drugs Sales Value Share by Type (2021-2032)
5 Hospital Injectable Drugs Market by Application
  1. 5.1 Hospital Injectable Drugs Application Introduction
  2. 5.1.1 Oncology
  3. 5.1.2 Anesthesia
  4. 5.1.3 Anti-Infectives
  5. 5.1.4 Parenteral Nutrition
  6. 5.1.5 Cardiovascular Diseases
  7. 5.2 Global Hospital Injectable Drugs Sales Value by Application
  8. 5.2.1 Global Hospital Injectable Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Hospital Injectable Drugs Sales Value by Application (2021-2032)
  10. 5.2.3 Global Hospital Injectable Drugs Sales Value Share by Application (2021-2032)
6 Hospital Injectable Drugs Regional Value Analysis
  1. 6.1 Global Hospital Injectable Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Hospital Injectable Drugs Sales Value by Region (2021-2032)
  3. 6.2.1 Global Hospital Injectable Drugs Sales Value by Region: 2021-2026
  4. 6.2.2 Global Hospital Injectable Drugs Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Hospital Injectable Drugs Sales Value (2021-2032)
  7. 6.3.2 North America Hospital Injectable Drugs Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Hospital Injectable Drugs Sales Value (2021-2032)
  10. 6.4.2 Europe Hospital Injectable Drugs Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Hospital Injectable Drugs Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Hospital Injectable Drugs Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Hospital Injectable Drugs Sales Value (2021-2032)
  16. 6.6.2 South America Hospital Injectable Drugs Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Hospital Injectable Drugs Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Hospital Injectable Drugs Sales Value Share by Country, 2025 VS 2032
7 Hospital Injectable Drugs Country-level Value Analysis
  1. 7.1 Global Hospital Injectable Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Hospital Injectable Drugs Sales Value by Country (2021-2032)
  3. 7.2.1 Global Hospital Injectable Drugs Sales Value by Country (2021-2026)
  4. 7.2.2 Global Hospital Injectable Drugs Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Hospital Injectable Drugs Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Hospital Injectable Drugs Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Hospital Injectable Drugs Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Hospital Injectable Drugs Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Hospital Injectable Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Hospital Injectable Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Hospital Injectable Drugs Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Hospital Injectable Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Hospital Injectable Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Hospital Injectable Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Hospital Injectable Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Hospital Injectable Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Hospital Injectable Drugs Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Hospital Injectable Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Hospital Injectable Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Hospital Injectable Drugs Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Hospital Injectable Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Hospital Injectable Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Hospital Injectable Drugs Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Hospital Injectable Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Hospital Injectable Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Hospital Injectable Drugs Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Hospital Injectable Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Hospital Injectable Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Hospital Injectable Drugs Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Hospital Injectable Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Hospital Injectable Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Hospital Injectable Drugs Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Hospital Injectable Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Hospital Injectable Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Hospital Injectable Drugs Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Hospital Injectable Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Hospital Injectable Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Hospital Injectable Drugs Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Hospital Injectable Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Hospital Injectable Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Hospital Injectable Drugs Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Hospital Injectable Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Hospital Injectable Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Hospital Injectable Drugs Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Hospital Injectable Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Hospital Injectable Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Hospital Injectable Drugs Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Hospital Injectable Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Hospital Injectable Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Hospital Injectable Drugs Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Hospital Injectable Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Hospital Injectable Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Hospital Injectable Drugs Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Hospital Injectable Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Hospital Injectable Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Hospital Injectable Drugs Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Hospital Injectable Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Hospital Injectable Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Hospital Injectable Drugs Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Hospital Injectable Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Hospital Injectable Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Hospital Injectable Drugs Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Hospital Injectable Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Hospital Injectable Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Hospital Injectable Drugs Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Hospital Injectable Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Hospital Injectable Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Hospital Injectable Drugs Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Hospital Injectable Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Hospital Injectable Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Hospital Injectable Drugs Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Hospital Injectable Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Hospital Injectable Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Hospital Injectable Drugs Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Hospital Injectable Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Hospital Injectable Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Hospital Injectable Drugs Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Hospital Injectable Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Hospital Injectable Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Hospital Injectable Drugs Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Hospital Injectable Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Hospital Injectable Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Hospital Injectable Drugs Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Hospital Injectable Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Hospital Injectable Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Hospital Injectable Drugs Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Hospital Injectable Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Hospital Injectable Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Hospira (Pfizer Inc.)
  2. 8.1.1 Hospira (Pfizer Inc.) Company Information
  3. 8.1.2 Hospira (Pfizer Inc.) Business Overview
  4. 8.1.3 Hospira (Pfizer Inc.) Hospital Injectable Drugs Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Hospira (Pfizer Inc.) Hospital Injectable Drugs Product Portfolio
  6. 8.1.5 Hospira (Pfizer Inc.) Recent Developments
  7. 8.2 Baxter
  8. 8.2.1 Baxter Company Information
  9. 8.2.2 Baxter Business Overview
  10. 8.2.3 Baxter Hospital Injectable Drugs Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Baxter Hospital Injectable Drugs Product Portfolio
  12. 8.2.5 Baxter Recent Developments
  13. 8.3 Fresenius Kabi
  14. 8.3.1 Fresenius Kabi Company Information
  15. 8.3.2 Fresenius Kabi Business Overview
  16. 8.3.3 Fresenius Kabi Hospital Injectable Drugs Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Fresenius Kabi Hospital Injectable Drugs Product Portfolio
  18. 8.3.5 Fresenius Kabi Recent Developments
  19. 8.4 Sandoz (Novartis)
  20. 8.4.1 Sandoz (Novartis) Company Information
  21. 8.4.2 Sandoz (Novartis) Business Overview
  22. 8.4.3 Sandoz (Novartis) Hospital Injectable Drugs Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Sandoz (Novartis) Hospital Injectable Drugs Product Portfolio
  24. 8.4.5 Sandoz (Novartis) Recent Developments
  25. 8.5 Hikma Pharmaceuticals PLC
  26. 8.5.1 Hikma Pharmaceuticals PLC Company Information
  27. 8.5.2 Hikma Pharmaceuticals PLC Business Overview
  28. 8.5.3 Hikma Pharmaceuticals PLC Hospital Injectable Drugs Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Hikma Pharmaceuticals PLC Hospital Injectable Drugs Product Portfolio
  30. 8.5.5 Hikma Pharmaceuticals PLC Recent Developments
  31. 8.6 Dr. Reddy’s Laboratories Ltd
  32. 8.6.1 Dr. Reddy’s Laboratories Ltd Company Information
  33. 8.6.2 Dr. Reddy’s Laboratories Ltd Business Overview
  34. 8.6.3 Dr. Reddy’s Laboratories Ltd Hospital Injectable Drugs Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Dr. Reddy’s Laboratories Ltd Hospital Injectable Drugs Product Portfolio
  36. 8.6.5 Dr. Reddy’s Laboratories Ltd Recent Developments
  37. 8.7 Grifols
  38. 8.7.1 Grifols Company Information
  39. 8.7.2 Grifols Business Overview
  40. 8.7.3 Grifols Hospital Injectable Drugs Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Grifols Hospital Injectable Drugs Product Portfolio
  42. 8.7.5 Grifols Recent Developments
  43. 8.8 Nichi-Iko Group (Sagent)
  44. 8.8.1 Nichi-Iko Group (Sagent) Company Information
  45. 8.8.2 Nichi-Iko Group (Sagent) Business Overview
  46. 8.8.3 Nichi-Iko Group (Sagent) Hospital Injectable Drugs Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Nichi-Iko Group (Sagent) Hospital Injectable Drugs Product Portfolio
  48. 8.8.5 Nichi-Iko Group (Sagent) Recent Developments
  49. 8.9 Teva Pharmaceutical
  50. 8.9.1 Teva Pharmaceutical Company Information
  51. 8.9.2 Teva Pharmaceutical Business Overview
  52. 8.9.3 Teva Pharmaceutical Hospital Injectable Drugs Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Teva Pharmaceutical Hospital Injectable Drugs Product Portfolio
  54. 8.9.5 Teva Pharmaceutical Recent Developments
  55. 8.10 Otsuka
  56. 8.10.1 Otsuka Company Information
  57. 8.10.2 Otsuka Business Overview
  58. 8.10.3 Otsuka Hospital Injectable Drugs Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Otsuka Hospital Injectable Drugs Product Portfolio
  60. 8.10.5 Otsuka Recent Developments
  61. 8.11 B.Braun
  62. 8.11.1 B.Braun Company Information
  63. 8.11.2 B.Braun Business Overview
  64. 8.11.3 B.Braun Hospital Injectable Drugs Revenue and Gross Margin (2021-2026)
  65. 8.11.4 B.Braun Hospital Injectable Drugs Product Portfolio
  66. 8.11.5 B.Braun Recent Developments
  67. 8.12 JW Life Science
  68. 8.12.1 JW Life Science Company Information
  69. 8.12.2 JW Life Science Business Overview
  70. 8.12.3 JW Life Science Hospital Injectable Drugs Revenue and Gross Margin (2021-2026)
  71. 8.12.4 JW Life Science Hospital Injectable Drugs Product Portfolio
  72. 8.12.5 JW Life Science Recent Developments
  73. 8.13 Auromedics
  74. 8.13.1 Auromedics Company Information
  75. 8.13.2 Auromedics Business Overview
  76. 8.13.3 Auromedics Hospital Injectable Drugs Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Auromedics Hospital Injectable Drugs Product Portfolio
  78. 8.13.5 Auromedics Recent Developments
  79. 8.14 Sanofi
  80. 8.14.1 Sanofi Company Information
  81. 8.14.2 Sanofi Business Overview
  82. 8.14.3 Sanofi Hospital Injectable Drugs Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Sanofi Hospital Injectable Drugs Product Portfolio
  84. 8.14.5 Sanofi Recent Developments
  85. 8.15 Gland Pharma
  86. 8.15.1 Gland Pharma Company Information
  87. 8.15.2 Gland Pharma Business Overview
  88. 8.15.3 Gland Pharma Hospital Injectable Drugs Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Gland Pharma Hospital Injectable Drugs Product Portfolio
  90. 8.15.5 Gland Pharma Recent Developments
  91. 8.16 Endo International PLC
  92. 8.16.1 Endo International PLC Company Information
  93. 8.16.2 Endo International PLC Business Overview
  94. 8.16.3 Endo International PLC Hospital Injectable Drugs Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Endo International PLC Hospital Injectable Drugs Product Portfolio
  96. 8.16.5 Endo International PLC Recent Developments
  97. 8.17 Sichuan Kelun Pharmaceutical
  98. 8.17.1 Sichuan Kelun Pharmaceutical Company Information
  99. 8.17.2 Sichuan Kelun Pharmaceutical Business Overview
  100. 8.17.3 Sichuan Kelun Pharmaceutical Hospital Injectable Drugs Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Sichuan Kelun Pharmaceutical Hospital Injectable Drugs Product Portfolio
  102. 8.17.5 Sichuan Kelun Pharmaceutical Recent Developments
  103. 8.18 Cisen Pharmaceutical
  104. 8.18.1 Cisen Pharmaceutical Company Information
  105. 8.18.2 Cisen Pharmaceutical Business Overview
  106. 8.18.3 Cisen Pharmaceutical Hospital Injectable Drugs Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Cisen Pharmaceutical Hospital Injectable Drugs Product Portfolio
  108. 8.18.5 Cisen Pharmaceutical Recent Developments
  109. 8.19 Shijiazhuang No. 4 Pharmaceutical
  110. 8.19.1 Shijiazhuang No. 4 Pharmaceutical Company Information
  111. 8.19.2 Shijiazhuang No. 4 Pharmaceutical Business Overview
  112. 8.19.3 Shijiazhuang No. 4 Pharmaceutical Hospital Injectable Drugs Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Shijiazhuang No. 4 Pharmaceutical Hospital Injectable Drugs Product Portfolio
  114. 8.19.5 Shijiazhuang No. 4 Pharmaceutical Recent Developments
  115. 8.20 Shandong Hualu Pharmaceutical
  116. 8.20.1 Shandong Hualu Pharmaceutical Company Information
  117. 8.20.2 Shandong Hualu Pharmaceutical Business Overview
  118. 8.20.3 Shandong Hualu Pharmaceutical Hospital Injectable Drugs Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Shandong Hualu Pharmaceutical Hospital Injectable Drugs Product Portfolio
  120. 8.20.5 Shandong Hualu Pharmaceutical Recent Developments
  121. 8.21 CR Double-Crane
  122. 8.21.1 CR Double-Crane Company Information
  123. 8.21.2 CR Double-Crane Business Overview
  124. 8.21.3 CR Double-Crane Hospital Injectable Drugs Revenue and Gross Margin (2021-2026)
  125. 8.21.4 CR Double-Crane Hospital Injectable Drugs Product Portfolio
  126. 8.21.5 CR Double-Crane Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst